Achilles Therapeutics Statistics
Share Statistics
Achilles Therapeutics has 41.10M shares outstanding. The number of shares has increased by 0.75% in one year.
| Shares Outstanding | 41.10M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 37.95M |
| Failed to Deliver (FTD) Shares | 9.64K |
| FTD / Avg. Volume | 1.38% |
Short Selling Information
The latest short interest is 159.25K, so 0.39% of the outstanding shares have been sold short.
| Short Interest | 159.25K |
| Short % of Shares Out | 0.39% |
| Short % of Float | 0.42% |
| Short Ratio (days to cover) | 1.69 |
Valuation Ratios
The PE ratio is -0.51 and the forward PE ratio is -0.54.
| PE Ratio | -0.51 |
| Forward PE | -0.54 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 0.25 |
| P/FCF Ratio | -0.72 |
| PEG Ratio | n/a |
Enterprise Valuation
Achilles Therapeutics has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 8.57, with a Debt / Equity ratio of 0.
| Current Ratio | 8.57 |
| Quick Ratio | 8.57 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.49% and return on capital (ROIC) is -51.56%.
| Return on Equity (ROE) | -0.49% |
| Return on Assets (ROA) | -0.43% |
| Return on Capital (ROIC) | -51.56% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -341.50K |
| Employee Count | 204 |
| Asset Turnover | 0 |
| Inventory Turnover | 4.73M |
Taxes
| Income Tax | 491.00K |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by 13.79% in the last 52 weeks. The beta is 1.34, so Achilles Therapeutics's price volatility has been higher than the market average.
| Beta | 1.34 |
| 52-Week Price Change | 13.79% |
| 50-Day Moving Average | 1.03 |
| 200-Day Moving Average | 0.93 |
| Relative Strength Index (RSI) | 34.71 |
| Average Volume (20 Days) | 698.09K |
Income Statement
In the last 12 months, Achilles Therapeutics had revenue of $0 and earned -$69.67M in profits. Earnings per share was $-1.74.
| Revenue | 0 |
| Gross Profit | -4.73M |
| Operating Income | -75.25M |
| Net Income | -69.67M |
| EBITDA | -70.44M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.74 |
Balance Sheet
The company has $131.54M in cash and $4.62M in debt, giving a net cash position of $126.92M.
| Cash & Cash Equivalents | 131.54M |
| Total Debt | 4.62M |
| Net Cash | 126.92M |
| Retained Earnings | -259.95M |
| Total Assets | 122.68M |
| Working Capital | 93.16M |
Cash Flow
In the last 12 months, operating cash flow was -$48.45M and capital expenditures -$1.10M, giving a free cash flow of -$49.55M.
| Operating Cash Flow | -48.45M |
| Capital Expenditures | -1.10M |
| Free Cash Flow | -49.55M |
| FCF Per Share | -1.24 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
ACHL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -175.76% |
| FCF Yield | -121.79% |
Analyst Forecast
The average price target for ACHL is $2, which is 102% higher than the current price. The consensus rating is "Hold".
| Price Target | $2 |
| Price Target Difference | 102% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -3.29 |
| Piotroski F-Score | 1 |